Media
[NEWS] Hua Medicine Will Present Multiple Research Findings at the 28th Annual Scientific Meeting of CDS
November 13, 2026, Shanghai, China
Hua Medicine ("the Company," Hong Kong Stock Exchange stock code: 2552.HK) today announced that it will present research findings on dorzagliatin, its first-in-class glucokinase activator (GKA), at the 28th Annual Meeting of the Chinese Diabetes Society (CDS) of the Chinese Medical Association, via symposia, e-posters and written abstract presentations.
The two symposia are themed The Theoretical Basis and Target Mechanism of Blood Glucose Homeostasis Regulation and Blood Glucose Homeostasis Management in Type 2 Diabetes Mellitus — From Mechanism to Clinical Practice. Centering on five key dimensions including post-marketing real-world studies, clinical treatment strategies, combination therapy, management in special patient populations, glucokinase (GK) mechanisms and precision diagnosis and treatment, they showcase Hua Medicine’s continuous and systematic scientific exploration in blood glucose homeostasis management. Additional evidence for glucokinase activator (GKA), translating from clinical trials to real-world clinical practice, will be further demonstrated in e-posters and written abstracts covering real-world research of dorzagliatin, blood glucose homeostasis management, and clinical treatment strategies for diverse patient cohorts.
Moreover, during the conference, Hua Medicine will set up a thematic booth themed around the concept of "blood glucose homeostasis". It will feature cutting-edge research advances in the GK field and launch an interactive demo of its self-developed AI tool "GK Power Bank". Tailored for GK/GKA research scenarios, this AI tool supports intelligent Q&A and retrieval of relevant academic content. Leveraging AI to empower professional academic knowledge exchange, it delivers an innovative academic interactive experience for conference attendees, as the Company joins industry peers to explore scientific progress in the GK field.
The 28th Annual Meeting of the Chinese Diabetes Society, hosted by the Chinese Medical Association and the Chinese Diabetes Society, will be held on November 18-21, in Xiamen, Fujian Province. The conference aims to advance diabetes research, prevention and treatment in China and support the Healthy China Initiative.
Hua Medicine Booth Information
Date: November 18-21, 2026
Venue: Xiamen International Conference & Exhibition Center
Booth No.:A10
Hua Medicine Conference Schedule
Hua Medicine Symposium
Time: Thursday, November 19, 2026
Venue: Multi-function Hall B4, Hall 6
12:30-13:30|Symposium: The Theoretical Basis and Blood Glucose Homeostasis Regulation and Target Mechanism | |||
Session Chairs: Li Xiaoying, Zhongshan Hospital, Fudan University Jiang Sheng, The First Affiliated Hospital of Xinjiang Medical University | |||
Time | Topic | Speaker | Affiliation |
12:30-12:50 | A Century of Glucose-Lowering Therapy toward Homeostasis: Drug Evolution from Glycemic Target Achievement to Homeostasis Management | Xu Yong | Affiliated Hospital of Southwest Medical University |
12:50-13:10 | Restoring Blood Glucose Homeostasis: Modern Interpretation of Homeostasis Theory | He Qing | Tianjin Medical University General Hospital |
13:10-13:30 | Mechanism of Glucokinase in Regulating Blood Glucose Homeostasis | Lu Jin | Changhai Hospital, the First Affiliated Hospital of Naval Medical University |
13:30 -14:30|Symposium: Blood Glucose Homeostasis Management in Type 2 Diabetes Mellitus — From Mechanism to Clinical Practice | |||
Session Chairs: Zhu Dalong, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School Wang Guang, Beijing Chaoyang Hospital, Capital Medical University | |||
Time | Topic | Speaker | Affiliation |
13:30-13:50 | Post-marketing Safety Research of Glucokinase Activators | Yang Wenying | China-Japan Friendship Hospital |
13:50-14:10 | Restoring Blood Glucose Homeostasis: Modern Interpretation of Homeostasis Theory | Ma Jianhua | Nanjing First Hospital |
14:10-14:30 | Mechanism of Glucokinase in Regulating Blood Glucose Homeostasis | Li Xiaomu | The First Affiliated Hospital, Zhejiang University School of Medicine |
E-Posters and Written Abstract Presentations
Presentation Type | Title |
E-Poster | Real-world Safety and Efficacy of Dorzagliatin in Elderly Patients with Type 2 Diabetes Mellitus: Age-Subgroup Analysis from a Multicenter Phase IV Study |
E-Poster | Glycemic Efficacy of Dorzagliatin in Patients with T2DM: Post-hoc Analysis of the SEED and DAWN Trials |
E-Poster | Real-world Safety and Efficacy of Dorzagliatin in Patients with Type 2 Diabetes Mellitus: Results from a Multicenter Phase IV Study |
E-Poster | Subgroup Analysis from a Prospective Real-world Study of Dorzagliatin: Improvement in Blood Glucose Homeostasis in Patients with Poor Glycemic Control on Multi-agent Antidiabetic Regimens |
E-Poster | Real-world Safety and Efficacy of Dorzagliatin in Elderly Patients with Type 2 Diabetes Mellitus: Age-Subgroup Analysis from a Multicenter Phase IV Study |
Written Abstract | Subgroup from a Prospective Real-world Study on Dorzagliatin-Mediated Improvement of Blood Glucose Homeostasis: Addition of Dorzagliatin in T2DM Patients with Inadequate Glycemic Control on GLP-1RA Therapy |
Written Abstract | Combination of Dorzagliatin and Orforglipron Ameliorates Abnormal Glucose and Lipid Metabolism in DIO Mice |
Written Abstract | Observational Study on Changes in Renal-related Indicators in Type 2 Diabetic Patients with Renal Impairment Treated with Dorzagliatin |
About Hua Medicine
Hua Medicine (the "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Drawing on global resources, Hua Medicine partners with high-calibre talent worldwide to develop breakthrough technologies and products that advance innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing(华堂宁®， dorzagliatin tablets) targets the glucose sensor glucokinase, restores glucose sensitivity in patients with Type 2 diabetes ("T2D"), and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30, 2022. It can be used alone or in combination with metformin for adult patients with T2D. For patients with chronic kidney disease, no dose adjustment is required. It is an oral glucose-lowering drug that can be used in T2D patients with renal function impairment.
In February 2026, dorzagliatin (trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Service of the Department of Health of the Government of the Hong Kong Special Administrative Region of the People's Republic of China.
In June 2026, dorzagliatin (trade name: MYHOMSIS®, 華領片®) was approved for marketing by the Pharmaceutical Administration Bureau of the Macao Special Administrative Region of the People's Republic of China.
Based on the International Diabetes Federation's 2025 Diabetes Atlas – 11th Edition, there are approximately 148 million diabetic patients in China, 706,000 diabetic patients in Hong Kong SAR, and 52,000 diabetic patients in Macao SAR as of 2024.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
